ProMIS Neurosciences’ Upcoming Conference Participation Details

Author: Owen Jenkins Updated: 01-29-2025 07:32 AM

ProMIS Neurosciences at the Guggenheim Securities Conference

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology firm, is gearing up for its participation in the Guggenheim Securities SMID Cap Biotech Conference, where Neil Warma, the company’s Chief Executive Officer, will lead a fireside chat. This significant event is scheduled for Wednesday, February 5, and sets the stage for a vital conversation regarding new developments in the biotechnology sector.

About ProMIS Neurosciences

ProMIS Neurosciences is committed to innovating in the realm of neurodegenerative diseases. The company focuses on exploring and developing targeted antibody therapeutics aimed at harmful misfolded proteins linked to conditions like Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). Their approach leverages a unique thermodynamic computational discovery platform, which is pivotal in identifying disease-specific epitopes on misfolded proteins - a technique valued in the biotechnology industry.

Innovative Therapeutic Development

Among ProMIS's notable projects is PMN310, which is tailored for Alzheimer's disease. PMN310 is a distinguished humanized monoclonal antibody developed with the capability to specifically target toxic A? oligomers while avoiding interactions with plaques or monomers. This specificity is crucial, given that oligomers notoriously drive the progression of Alzheimer's. Recent studies have shown promising outcomes, indicating that PMN310 could support enhanced safety and efficacy in treatment.

Clinical Trial Progress

The journey of PMN310 through the clinical trial process has yielded encouraging results. It has successfully completed a Phase 1a clinical study, and ProMIS has now launched a Phase 1b clinical trial including patients with Alzheimer's. This represents a pivotal step toward potential market entry and approval, aligning with ProMIS’s mission to deliver effective treatments for detrimental neurodegenerative diseases.

Engagement and Future Outlook

As ProMIS Neurosciences continues to advance its clinical programs, the company maintains a focus on strategic engagements and partnerships that could amplify their market presence and scientific impact. Participation in events like the Guggenheim Securities Conference allows them to showcase their innovations and connect with key stakeholders, investors, and fellow biotech enterprises.

Company Contact Information

For more details or inquiries, ProMIS Neurosciences can be contacted through Precision AQ, formerly known as Stern IR. Anne Marie Fields, Managing Director, is available at 212-362-1200 for investor relations matters. Furthermore, direct inquiries can be made through info@promisneurosciences.com.

Frequently Asked Questions

What is the focus of ProMIS Neurosciences?

ProMIS Neurosciences is dedicated to developing antibody therapeutics aimed at neurodegenerative diseases such as Alzheimer's, ALS, and MSA.

Who will represent ProMIS at the conference?

Neil Warma, the CEO of ProMIS Neurosciences, will represent the company during a fireside chat at the conference.

What product is ProMIS currently developing for Alzheimer's?

PMN310 is ProMIS's lead product candidate that targets toxic A? oligomers associated with Alzheimer's disease.

What stage is PMN310 currently in?

PMN310 has completed a Phase 1a clinical study and has initiated a Phase 1b clinical trial.

How can I get in touch with ProMIS for more information?

For inquiries, you can reach ProMIS Neurosciences via email at info@promisneurosciences.com or contact their investor relations through Anne Marie Fields at 212-362-1200.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.